These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22379688)

  • 21. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current good manufacturing practices, quality control procedures, quality factors, notification requirements, and records and reports, for infant formula. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(111):33057-72. PubMed ID: 24922980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
    Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical devices; medical device distributor reporting--FDA. Final rule; notification of status under the Safe Medical Devices Act; confirmation of effective date.
    Fed Regist; 1993 Sep; 58(168):46514-23. PubMed ID: 10128335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical devices; medical device reporting. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Feb; 70(38):9516-28. PubMed ID: 15736310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical devices; device tracking. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(27):5943-52. PubMed ID: 11838471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical devices: reports of corrections and removals; delay of effective data--FDA. Direct final rule; delay of effective date.
    Fed Regist; 1998 Nov; 63(222):63983. PubMed ID: 10339047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General administrative rulings and decisions; amendment to the examination and investigation sample requirements; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Sep; 63(186):51322-4. PubMed ID: 10185811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior notice of imported food under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Nov; 73(217):66293-410. PubMed ID: 19112701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Interim final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34959-69. PubMed ID: 17674485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastroenterology-urology devices; effective date of requirement for premarket approval of the penile inflatable implant. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Apr; 65(71):19650-8. PubMed ID: 11010632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importing a change in diet: the proposed food safety law of 2010 and the possible impact on importers and international trade.
    May SG
    Food Drug Law J; 2010; 65(1):1-35, i. PubMed ID: 24475533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.